ZYBERNO
Stock Report
Updated Sep 1, 2026

PROPANC BIOPHARMA, INC. (PPCB)

Healthcare • NASDAQ

$1.13

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
PROPANC BIOPHARMA, INC. (PPCB) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-151.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-145.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PROPANC BIOPHARMA, INC. (PPCB) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.13
Market Cap:$3.96M

Valuation Multiples (2)

P/B Ratio:0.40x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.59M

Price Action & Momentum (1)

B. Profitability Assessment

Return Metrics (5)

ROA:-109.5%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$272.13
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:97.8%
Latest Earnings Filed:2026-05-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.37x
Quick Ratio:2.37x
Cash Ratio:0.13x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-87.13x
Times Interest Earned:-87.13

Capital Structure (4)

Working Capital:4,747,860.00
Cash And Cash Equivalents:443,702.00
Long Term Debt:$55.00K
Net Debt:-$365.38K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$18.37M

Bottom Line Performance (3)

-$18.36M
Income Before Tax:-$18.36M
Ebitda Ttm:-18,373,468.00

Operating Expenses (5)

Operating Expenses:18,373,765.00
R And D Expense:303,344.00
Sga Expense:18,031,742.00
Income Tax Expense:$0.00
Interest Expense:657,416.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$14.33M
Current Assets:$8.22M
Ppe Net:31,181.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,505,895.00
Current Liabilities:3,475,628.00
Long Term Debt:$55.00K
Short Term Debt:$23.32K

Equity & Capital (3)

Equity:$9.83M
Retained Earnings:-$140.84M
Common Stock:10,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:973,692.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:5,351,136.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.11M-$408.04K

Investment Activities (1)

Investing Cash Flow:-$2.49K

Financing Activities (3)

Financing Cash Flow:$2.53M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,314,458.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$671.78K
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.32
-$3.32
Earnings Per Share Ttm:-$5.24

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.12

Book Value & Capital (2)

Book Value Per Share:$2.81
Cash Per Share:0.13

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-45.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:PPCB
Company Name:PROPANC BIOPHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Australia

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.50M
Shares Outstanding Basic:22.43M
Shares Outstanding Diluted:22.43M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:30:45 UTC
Data Timestamp:2026-08-22T10:13:10.645978
Scroll to Top